ReviewFrontiers in molecular neuroscience2026
Nanomaterial modulation of lysosomal homeostasis in neurodegenerative proteinopathies: from pathological-protein degradation to re-release and seeding.
Review in Frontiers in molecular neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Misfolded and aggregated proteins are central to neurodegenerative proteinopathies, yet a reduction in intracellular protein burden does not necessarily indicate productive clearance, because incompletely processed cargo may be re-released and retain seeding competence. This review examines how nanomaterials targeting lysosomal homeostasis may promote complete degradation of pathological proteins while limiting the re-release of incompletely processed species and their residual seeding activity. PubMed records published from July 2021 to July 2026 were prioritised, with earlier foundational studies included selectively, and evidence was classified as direct disease-model evidence, mechanistic support, or platform extrapolation. Across Aβ, tau, α-synuclein, polyglutamine-expanded proteins, and SOD1-related pathology, effective clearance depends on protein conformation, cell type, lysosomal acidification and hydrolase activity, autophagic transport, lipid processing, membrane integrity, and cellular bioenergetics. Current evidence is strongest for restoration of lysosomal acidity, hydrolase function, and autophagic processing; support for durable lipid and membrane correction is less complete, and direct evidence for reduced re-release and seed inactivation remains scarce. No reviewed study simultaneously demonstrated lysosomal restoration, complete degradation of a defined pathological substrate, reduced extracellular release, and direct seed inactivation. Future evaluation should therefore integrate brain, cell-specific and organelle delivery, substrate turnover, extracellular cargo, direct seeding assays, and repeated-dose lysosomal safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.